- Main
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
- Short, Nicholas J;
- Kantarjian, Hagop;
- Ravandi, Farhad;
- Huang, Xuelin;
- Xiao, Lianchun;
- Garcia-Manero, Guillermo;
- Plunkett, William;
- Gandhi, Varsha;
- Sasaki, Koji;
- Pemmaraju, Naveen;
- Daver, Naval G;
- Borthakur, Gautam;
- Jain, Nitin;
- Konopleva, Marina;
- Estrov, Zeev;
- Kadia, Tapan M;
- Wierda, William G;
- DiNardo, Courtney D;
- Brandt, Mark;
- O'Brien, Susan M;
- Cortes, Jorge E;
- Jabbour, Elias
Published Web Location
https://doi.org/10.1080/10428194.2017.1349907Abstract
The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m2 was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n = 48) or FIA (n = 33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p = .50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p = .48), and the median overall survival was 6.3 and 4.7 months, respectively (p = .28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.